Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 18 | 2017 | 312 | 2.770 |
Why?
|
| Endometrial Neoplasms | 9 | 2019 | 66 | 2.440 |
Why?
|
| DNA Mismatch Repair | 4 | 2016 | 25 | 1.550 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 336 | 0.850 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 251 | 0.810 |
Why?
|
| Ovarian Cysts | 1 | 2017 | 2 | 0.610 |
Why?
|
| Hysterectomy | 2 | 2017 | 28 | 0.590 |
Why?
|
| Middle Aged | 26 | 2019 | 10129 | 0.590 |
Why?
|
| Ovary | 2 | 2017 | 108 | 0.580 |
Why?
|
| Vulvar Neoplasms | 2 | 2006 | 12 | 0.540 |
Why?
|
| Carcinosarcoma | 2 | 2013 | 4 | 0.540 |
Why?
|
| Postmenopause | 3 | 2014 | 128 | 0.540 |
Why?
|
| Aged | 21 | 2019 | 6741 | 0.520 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 82 | 0.510 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2014 | 15 | 0.510 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 9 | 0.490 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2014 | 18 | 0.490 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 14 | 0.490 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 18 | 0.490 |
Why?
|
| Retrospective Studies | 7 | 2017 | 2026 | 0.470 |
Why?
|
| Female | 29 | 2019 | 20969 | 0.440 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 494 | 0.390 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2017 | 7 | 0.380 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 275 | 0.340 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 2379 | 0.340 |
Why?
|
| Humans | 29 | 2019 | 37093 | 0.320 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 65 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2011 | 628 | 0.310 |
Why?
|
| Adult | 19 | 2019 | 11712 | 0.300 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2008 | 40 | 0.290 |
Why?
|
| Aneuploidy | 1 | 2004 | 23 | 0.250 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1502 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2011 | 767 | 0.250 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 92 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 178 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2018 | 191 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 128 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 251 | 0.200 |
Why?
|
| Carboplatin | 2 | 2019 | 13 | 0.190 |
Why?
|
| Proteins | 2 | 2015 | 369 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 16 | 0.170 |
Why?
|
| Pelvis | 1 | 2019 | 14 | 0.170 |
Why?
|
| Vagina | 1 | 2019 | 81 | 0.170 |
Why?
|
| Paclitaxel | 1 | 2019 | 50 | 0.160 |
Why?
|
| Haemophilus parasuis | 1 | 2018 | 1 | 0.160 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2018 | 11 | 0.160 |
Why?
|
| Case-Control Studies | 11 | 2011 | 1130 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2018 | 74 | 0.160 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2008 | 12 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2017 | 3 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2017 | 9 | 0.150 |
Why?
|
| Swine | 1 | 2018 | 184 | 0.150 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 60 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2017 | 67 | 0.150 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 125 | 0.140 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pregnancy, Ectopic | 1 | 2016 | 14 | 0.140 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2016 | 13 | 0.140 |
Why?
|
| Hawaii | 6 | 2016 | 1929 | 0.140 |
Why?
|
| Ibuprofen | 1 | 2016 | 32 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 400 | 0.140 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 22 | 0.140 |
Why?
|
| Vaccination | 1 | 2018 | 288 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 214 | 0.140 |
Why?
|
| Menopause | 1 | 2016 | 56 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2019 | 1378 | 0.130 |
Why?
|
| Biopsy | 1 | 2016 | 164 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 121 | 0.130 |
Why?
|
| Endometrium | 1 | 2016 | 60 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2014 | 753 | 0.120 |
Why?
|
| Risk Factors | 6 | 2016 | 3562 | 0.120 |
Why?
|
| Germ Cells | 1 | 2015 | 73 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 86 | 0.120 |
Why?
|
| Testis | 1 | 2015 | 187 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2013 | 17 | 0.110 |
Why?
|
| Mortality | 1 | 2014 | 145 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 236 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 20 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2012 | 31 | 0.110 |
Why?
|
| Pregnancy | 2 | 2016 | 1549 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 82 | 0.100 |
Why?
|
| Cell Survival | 1 | 2015 | 864 | 0.100 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adolescent | 4 | 2017 | 5363 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 190 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 4268 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2008 | 15 | 0.080 |
Why?
|
| Aryldialkylphosphatase | 1 | 2008 | 10 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 539 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 40 | 0.080 |
Why?
|
| Genotype | 5 | 2008 | 730 | 0.080 |
Why?
|
| Carcinoma | 1 | 2008 | 96 | 0.080 |
Why?
|
| Progestins | 1 | 2007 | 12 | 0.070 |
Why?
|
| Alleles | 4 | 2011 | 321 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1398 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2007 | 69 | 0.070 |
Why?
|
| Anovulation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Estrogens | 1 | 2007 | 202 | 0.060 |
Why?
|
| Logistic Models | 4 | 2008 | 923 | 0.060 |
Why?
|
| Interleukins | 1 | 2004 | 29 | 0.060 |
Why?
|
| Premenopause | 1 | 2005 | 104 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2006 | 1369 | 0.060 |
Why?
|
| Survival Rate | 1 | 2004 | 311 | 0.060 |
Why?
|
| Reproduction | 1 | 2003 | 71 | 0.060 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Galactose | 1 | 2002 | 8 | 0.050 |
Why?
|
| Lactose | 1 | 2002 | 14 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1067 | 0.050 |
Why?
|
| Dairy Products | 1 | 2002 | 35 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 182 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 213 | 0.050 |
Why?
|
| Contraceptives, Oral | 3 | 2005 | 14 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2019 | 7 | 0.040 |
Why?
|
| Los Angeles | 3 | 2008 | 380 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 480 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2002 | 454 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 70 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2015 | 19 | 0.030 |
Why?
|
| Risk | 2 | 2008 | 267 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2015 | 77 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 207 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 23 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 70 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 435 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 513 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2002 | 534 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 15081 | 0.020 |
Why?
|
| North Carolina | 1 | 2008 | 104 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 225 | 0.020 |
Why?
|
| SEER Program | 1 | 2008 | 91 | 0.020 |
Why?
|
| Maternal Age | 1 | 2008 | 26 | 0.020 |
Why?
|
| Epithelium | 1 | 2008 | 79 | 0.020 |
Why?
|
| Male | 2 | 2018 | 20025 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 381 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 854 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 448 | 0.020 |
Why?
|
| Registries | 1 | 2008 | 335 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 352 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1908 | 0.020 |
Why?
|
| Reproductive History | 1 | 2005 | 19 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1033 | 0.020 |
Why?
|
| Gravidity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2003 | 4 | 0.010 |
Why?
|
| Menstruation | 1 | 2003 | 10 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2005 | 113 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 100 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 1742 | 0.010 |
Why?
|
| Second-Look Surgery | 1 | 2002 | 1 | 0.010 |
Why?
|
| Floxuridine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 3 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 13 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 9 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 12 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 938 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 72 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 661 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 313 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 268 | 0.010 |
Why?
|
| California | 1 | 2002 | 476 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 739 | 0.010 |
Why?
|